| Name | Title | Contact Details |
|---|
Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression. When working correctly, the immune system can respond aggressively and with precise targeting to eliminate infectious pathogens or cancer cells. Incorrect regulation can cause the immune system to attack healthy tissue as foreign, supporting onset and progression of autoimmune disease while disruption of anti-tumor immune responses can shield cancer cells from the immune system and allow them to proliferate. Lycera is rapidly building a portfolio of selective immune modulators with mechanisms we believe will translate into improved outcomes for patients. With senior leadership and a team of scientists who represent the best of their fields, Lycera has the expertise and insight necessary to develop innovative therapies able to restore immune balance and significantly improve treatment for patients affected by these diseases around the world. Lycera product development programs are enhanced by our established global relationships with many leading chemists, scientists and clinical researchers. We are currently advancing novel small molecule compounds from distinct, yet complementary, areas of research, including immune metabolism, cell signaling and immune cell differentiation.
LifeNexus is the creator of iChip, a product that empowers consumers with their health information anywhere they need it. By working with health plans, employers and providers, we`re helping to create better healthcare experiences when it matters most.
Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.
Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.
Plenum Scientific Research, Inc is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.